Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Recommendation of “Hold” by Analysts
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
Banque Pictet & Cie SA Acquires Shares of 5,109 Arcellx, Inc. $ACLX
Gilead Extends Tender Offer to Acquire Arcellx
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders?
Bamco Inc. NY Has $45.17 Million Stake in Arcellx, Inc. $ACLX
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
Are ACLX, DBRG, AVO, CVGW Obtaining Fair Deals for their Shareholders?
The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning the Merger—ACLX, VRE, EHAB, and CECO
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of “Hold” from Analysts
Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders
Top 2 Health Care Stocks That May Crash This Quarter
Baron Health Care Fund Q4 2025 Contributors And Detractors
Arcellx President Sells $10M Worth of Shares After Acquisition Announcement
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy
First Look: Gilead buys Arcellx; IBM sinks on AI; Bitcoin slides
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX
Are ACLX, VRE, UHG, EHAB Obtaining Fair Deals for their Shareholders?
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Arcellx, Inc. (NASDAQ: ACLX)
Here's Why Shares of Arcellx Are Up Almost 80% Today
Gilead Sciences Expands Oncology Portfolio with Arcellx Acquisition
Stocks Slide After Trump's Tariff Hike
Shareholder Alert: The Ademi Firm investigates whether Arcellx Inc. is obtaining a Fair Price for its Public Shareholders
Shareholder Alert: The Ademi Firm investigates whether Arcellx Inc. is obtaining a Fair Price for its Public Shareholders
Why is Arcellx stock up 80% today? Gilead's $7.8B answer
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
Gilead to acquire Arcellx for $7.8 billion
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition
Federated Hermes Inc. Cuts Position in Arcellx, Inc. $ACLX
Ken Fisher's Strategic Moves: iShares 7-10 Year Treasury Bond ETF Takes Center Stage
Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder
Arcellx Director Sells 6,000 Shares for $450,000
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year?
Christopher Heery Sells 5,882 Shares of Arcellx (NASDAQ:ACLX) Stock
Here Are Monday’s Top Wall Street Analyst Research Calls: BlackSky Technology, Cummins, Lamb Watson, Ollie’s Bargain Outlet, Sealed Air, Volaris, and More
Arcellx: Funded Into 2028 With Strong Clinical Data
Why Is Arcellx Stock Surging Today?